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The Health Improvement Network UK primary care database was used to identify a cohort of 
38 077 individuals aged 50–84 years with a first prescription of low-dose acetylsalicylic acid (ASA; 
75–300 mg/day) for secondary prevention of cardiovascular or cerebrovascular events during 
2000–2007 . From this cohort, 169 incident cases of upper gastrointestinal bleeding (UGIB) were 
identified. Controls with no UGIB (n = 2000) were frequency-matched to the cases by age, sex, 
and follow-up time. A nested case–control analysis was performed to determine risk factors 
associated with UGIB. The incidence of UGIB was 1.1 per 1000 person-years (95% CI, 1.0–1.3). 
Low-dose ASA users with a history of peptic ulcer disease had an increased risk of UGIB compared 
with those without (Relative Risk [RR], 4.59; 95% CI, 2.87–7 .33). Concomitant use of ASA and 
clopidogrel (RR, 1.61; 95% CI, 0.85–3.05) or non-steroidal anti-inflammatory drugs (NSAIDs; RR, 
2.92; 95% CI, 1.77–4.82) conferred an increased risk of UGIB compared with ASA monotherapy. 
Discontinuation of ASA therapy (RR: 0.71, 95% CI, 0.42–1.20) and PPI co-treatment given since 
the start of ASA therapy (RR, 0.56; 95% CI, 0.33–0.96) were associated with a reduced risk of 
UGIB. In conclusion, in a cohort of individuals receiving low-dose ASA for secondary prevention 
of cardiovascular or cerebrovascular events, patients with a history of peptic ulcer disease, or 
who were receiving clopidogrel or NSAIDs had an increased risk of UGIB. The prescription of 
PPI therapy at the initiation of low-dose ASA reduced the risk of UGIB by almost half.
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with an increased risk of UGIB among a cohort of   individuals 
starting low-dose ASA therapy for secondary prevention of 
cardiovascular events.
Materials and Methods
data source
The Health Improvement Network (THIN) covers about 5% of the 
UK population, and is age, sex, and geographically representative 
(Bourke et al., 2004). Anonymized data on over 3 million patients 
are systematically recorded by participating primary care practitioners 
(PCPs) as part of their routine patient care and sent to THIN for use 
in research projects. The computerized information includes demo-
graphics, details from PCP visits, diagnoses, referrals to specialists 
and hospital admissions, results of laboratory tests, and a free-text 
section. Participating practices are required to record the indication 
for new courses of therapy, and prescriptions issued by the PCP are 
also recorded. The Read classification is used to code specific diagnoses 
(O’Neil et al., 1995; Stuart-Buttle et al., 1996), and a drug dictionary 
based on data from the MULTILEX classification is used to record 
prescriptions (First Data Bank, 2010). THIN has been extensively 
validated for use in pharmacoepidemiology (Lewis et al., 2007).
study design
From THIN, a cohort of new users of low-dose ASA (75–300 mg/
day) for secondary prevention of cardiovascular ischemic diseases 
or cerebrovascular ischemic events who were aged 50–84 years 
introduction
Evidence-based guidelines recommend long-term use of low-dose 
acetylsalicylic acid (ASA; 75–150 mg/day) for all patients with 
ischemic cardiovascular disease, unless contraindicated (Sacco 
et al., 2006; Smith et al., 2006; King et al., 2008). Low-dose ASA 
is known to be effective for the prevention of cardiovascular 
events in high-risk patients, reducing the risk of serious vascular 
events by around 25% (Antithrombotic Trialists’ Collaboration, 
2002). However, low-dose ASA is also known to increase the risk 
of upper gastrointestinal bleeding (UGIB) (Lanas et al., 2007). 
Numerous observational studies have shown that the risk of upper 
gastrointestinal complications in patients receiving low-dose ASA 
is around twofold that in the general population (Weil et al., 
1995; de Abajo and García Rodríguez, 2001; García Rodríguez 
et al., 2001).
Therefore, the cardiovascular benefits of low-dose ASA therapy 
should be weighed against the risk of any major bleeding, includ-
ing UGIB. Risk factors for UGIB in patients taking ASA are not 
well characterized, but appear to include advanced age, history of 
peptic ulcer disease and concomitant use of NSAIDs (Patrono et al., 
2005). A dose of ASA not greater than 81 mg per day together with 
a gastroprotective medication is recommended for patients at high 
risk of bleeding (Bhatt et al., 2008).
The aims of this study were to estimate the incidence of 
UGIB in a UK primary care setting and, through a nested case–
control analysis, establish the principal risk factors associated Frontiers in Pharmacology | Inflammation Pharmacology    October 2010  | Volume 1  |  Article 126  |  2
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data on the number of PCP visits, referrals and hospitalizations 
were collected for the year prior to the index date. Finally, informa-
tion on drug exposure between the start date and the index date 
was reviewed.
Exposure to antiplatelet drugs (ASA, clopidogrel and dipy-
ridamole), warfarin, nitrates, proton pump inhibitors (PPIs), 
histamine-2 receptor antagonists (H2RAs), oral steroids was clas-
sified as follows: current use, when the supply of the most recent 
prescription lasted until the index date or ended in the 30 days 
before the index date; past use, when supply of the most recent 
prescription ended 31–365 days before the index date; and non-
use when supply of the most recent prescription ended more than 
365 days before the index date or there was no recorded use at 
any time between the start and index dates if that interval was 
smaller than 365 days. Additionally we evaluated the interaction 
between dual antiplatelet use (ASA + clopidogrel) and between 
ASA + NSAIDs, independently. We created five levels of exposure 
for each of these two variables as follows: Non-use of either agent 
(within the year prior to index date); use of both agents defined as 
current users of the two agents; current use of only one agent and 
non-use of the other agent within the year prior and vice versa; and 
remaining (combinations of recency of both agents).
To estimate the effect of low-dose ASA discontinuation on 
the risk of UGIB, we categorized ASA exposure using the fol-
lowing time windows: current use, when the supply of the most 
recent prescription lasted until the index date (assuming com-
plete adherence) or ended in the 14 days before the index date; 
recent discontinuation when it ended 15–180 days before the index 
date; past discontinuation when it ended 181–365 days before 
the index date; and non-use when it ended more than 365 days 
before the index date. We also examined the reasons for low-
dose ASA discontinuation and classified them into four mutually 
exclusive groups: lack of efficacy, defined as physician-initiated 
switching from low-dose ASA to another antiplatelet drug or to 
an anticoagulant such as warfarin with no evidence to suggest 
an adverse event; safety concerns, defined as evidence of adverse 
events related to low-dose ASA therapy (such as upper gastrointes-
tinal disorders or UGIB), evidence of intolerance to low-dose ASA 
(allergy/urticaria), initiation of acid-suppressing drug treatment, 
or planned surgery; use of over-the-counter ASA, defined as when 
the PCP recorded that patients were receiving low-dose ASA in the 
absence of a computerized prescription or when the PCP noted 
that the patient was taking over-the-counter low-dose ASA; and 
non-adherence, defined as discontinuation in the absence of any 
of the above factors.
We subdivided current users of PPIs and H2RAs into two 
mutually exclusive groups: those who received their first pre-
scription before or at the start date (defined as users initiating 
therapy at start date) and those who received their first prescrip-
tion after the start date (defined as users initiating therapy after 
start date).
Exposure to NSAIDs was classified as follows: current use, 
when the supply of the most recent prescription lasted until 
the index date or ended in the 7 days before the index date (this 
shorter time window for NSAID current use was used to make it 
comparable with prior NSAID studies); past use, when it ended 
8–365 days before the index date; and non-use when use ended 
between 1 January 2000 and 31 December 2007 was sampled. They 
were required to be registered for at least 2 years with their PCP 
and to have at least 1 year of computerized prescription history. 
We excluded all individuals with any of the following conditions: 
alcohol abuse, cancer, coagulopathies, esophageal varices, liver dis-
ease or Mallory–Weiss disease. The date of the first ever recorded 
prescription of low-dose ASA for secondary prevention of cardio-
vascular or cerebrovascular events was defined as the start date. All 
study cohort members (N = 38 077) were followed for a mean of 
4.0 years from the first day after the start date until the earliest of 
the following endpoints: UGIB event; diagnosis of alcohol abuse/
alcohol-related disease, cancer, coagulopathy, esophageal varices, 
liver disease, or Mallory–Weiss disease; reaching the age of 85 years; 
death or the end of the study period (30 October 2008). The study 
was approved by a Multicentre Research Ethics Committee.
ugiB case ascertainMent
After removing all personal identifiers, we reviewed the free-text 
comments and patient profiles which included demographic data 
and all clinical information for all individuals with a computer-
recorded entry suggesting a UGIB event (n = 548). At this stage, 
patients were excluded if they had bleeding in a location other 
than the stomach or duodenum, or if they had no specific bleeding 
site recorded (unless it was recorded as “peptic ulcer”). Individuals 
were also excluded if they had gastrointestinal perforation, if the 
UGIB event was not confirmed upon further investigation or if 
they were not referred, or if they had a diagnosis of alcohol abuse/
alcohol-related disease, cancer, coagulopathy, esophageal varices, 
liver disease, or Mallory–Weiss disease. During the manual review, 
we also established the index date as the day of the first sign (e.g. 
bleeding) that led to the diagnosed outcome.
Following this review process, 169 patients were considered to 
be incident cases of UGIB (Figure 1). The site of bleeding was 
located in the stomach in 71 (42%) patients, in the duodenum for 
50 (29.6%), in both sites for 27 (16.0%), and in 21 (12.4%) patients 
the specific site was only recorded as “peptic ulcer”.
selection of controls
A date within the study period was generated at random for each 
member of the study cohort of 38 077 individuals. If the ran-
dom date was included in the individual’s eligible person-time 
(  follow-up period), we marked that person as an eligible control. 
The random date for controls was used as the index date in the 
nested case–control analysis. In total, 2000 controls, frequency-
matched by sex, age, and follow-up time (interval between start 
date and index date), were sampled. The same exclusion criteria 
were applied to controls as to cases.
coMorBidities and risk factors
Information on comorbidities was collected from THIN from any 
time before the start date. Peptic ulcer antecedents was categorized 
into three groups: dyspepsia which included all diagnoses related 
with upper gastrointestinal symptoms; uncomplicated peptic ulcer; 
and complicated peptic ulcer defined as all individuals with bleeding 
or another complication. Data on potential risk factors, such as 
smoking, alcohol use (units per week), body mass index (BMI; kg/
m2) were collected from any time before the index date. In addition, www.frontiersin.org  October 2010  | Volume 1  |  Article 126  |  3
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statistical analysis
The overall incidence of UGIB was estimated along with age- and 
sex-specific incidence estimates, and 95% confidence intervals (CIs) 
were calculated. We also calculated the incidence of UGIB in sub-
groups of ASA users with or without a history of peptic ulcer disease 
before the start date. Kaplan–Meier survival analysis and log rank 
test was performed in the whole cohort as well as stratified by sex, 
age, and history of peptic ulcer disease.
Nested case–control analysis was performed to estimate the asso-
ciation between various risk factors and the occurrence of UGIB. 
Odds ratios (ORs) and 95% CIs were calculated by unconditional 
multiple logistic regression models adjusted for age, sex, follow-up 
more than 365 days before the index date or there was no recorded 
use at any time between the start and index dates if that interval 
was smaller than 365 days. Current use of NSAIDs was further 
subdivided into the following categories: single, when there was 
use of only one NSAID in the 90 days before the index date, and 
multiple, when the patient used more than one NSAID in the 
90 days before the index date. Dose– and duration–response 
were assessed in current users of single NSAIDs. Duration of 
treatment was computed by summing the number of days cor-
responding to consecutive prescriptions (allowing for an interval 
of 60 days or less between the end of one prescription and the 
start of the next one).
Figure 1 | Study design and case ascertainment. UGIB, upper gastrointestinal bleeding.Frontiers in Pharmacology | Inflammation Pharmacology    October 2010  | Volume 1  |  Article 126  |  4
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time, history of peptic ulcer disease, PCP visits, number of  referrals 
and hospitalizations, and use of ASA, clopidogrel, warfarin, PPIs 
and NSAIDs (current, past, or no use). Under the study design of 
incidence density sampling, the OR is an unbiased estimator of 
the incidence rate ratio (RR). Statistical analyses were performed 
using Stata package version 11.0 (StataCorp LP, College Station, 
TX, USA).
results
incidence of ugiB
We observed a crude incidence of UGIB of 1.12 per 1000 person-
years (95% CI, 0.96–1.30). The incidence of UGIB increased with 
age and was slightly higher among men 1.18 (95% CI, 0.97–1.43) 
than women 1.05 (95% CI, 0.83–1.33) (Figure 2). There was 
no significant association between UGIB and sex (log rank test 
p value = 0.44), but older age was associated with UGIB (>70 years 
vs ≤70 years; log rank test p value = 0.0003).
The incidence of UGIB was 3.53 per 1000 person-years (95% 
CI, 2.53–4.92) among individuals with a previous diagnosis of pep-
tic ulcer disease, 1.44 per 1000 person-years (95% CI, 1.09–1.92) 
among individuals with a previous diagnosis of gastritis or dyspep-
sia, compared with 0.80 per 1000 person-years (95% CI, 0.65–0.99) 
among individuals with none of these diagnoses.
The cumulative proportion of patients developing UGIB over 
time is presented in Figure 3. The incidence during the first year 
of follow-up was 1.71 (95% CI, 1.34–2.20) per 1000 person-years 
and 0.93 (95% CI, 0.77–1.13) per 1000 person-years during the 
remaining years of follow-up. Figures 4–6 present the cumulative 
proportion of patients developing UGIB according to sex, age, and 
history of peptic ulcer disease, respectively.
risk factors for ugiB
Associations between baseline characteristics and comorbidities 
and the risk of UGIB are shown in Table 1. Consumption of more 
than 25 units of alcohol per week was associated with a significant 
increase in the risk of UGIB (RR, 2.96; 95% CI, 1.43–6.15; compared 
with non-use). The corresponding estimate of RR among current 
smokers was 1.33 (95% CI, 0.80–2.21 compared with non-smokers. 
Prior diagnosis of peptic ulcer disease (with or without complica-
tion) was also associated with a significant increase in the risk of 
UGIB (RR, 4.59; 95% CI, 2.87–7.33).
The RR of UGIB associated with current use of low-dose ASA 
was 1.63 (95% CI, 0.85–3.13) (Table 2). The risk of UGIB was sig-
nificantly increased in those receiving ASA 150–300 mg/day (RR, 
2.65; 95% CI, 1.17–5.97). The corresponding RR among those 
receiving 75 mg/day was 1.54 (95% CI, 0.80–2.97).
Current use of clopidogrel (with or without low-dose ASA) was 
associated with a significant increase in the risk of UGIB com-
pared with non-use (RR, 1.90; 95% CI, 1.12–3.22). Current users 
of dual antiplatelet therapy (ASA and clopidogrel) had a signifi-
cantly higher risk of UGIB than individuals using neither antiplate-
let therapy (RR, 3.31; 95% CI, 1.18–9.24) and a non-significant 
increase in the risk of UGIB compared with those using low-dose 
ASA monotherapy (RR, 1.61; 95% CI, 0.85–3.05).
Recent discontinuers of low-dose ASA had a lower risk of UGIB 
compared with those who continued low-dose ASA therapy (RR, 
0.71; 95% CI, 0.42–1.20; Table 3). When we examined the risk of 
Figure 2 | incidence of ugiB by age and sex in a cohort of low-dose ASA 
users. ASA, acetylsalicylic acid; UGIB, upper gastrointestinal bleeding.
Figure 3 | Cumulative proportion of patients developing ugiB during 
follow-up. UGIB, upper gastrointestinal bleeding.
Figure 4 | Cumulative proportion of patients developing ugiB, stratified 
by sex. UGIB, upper gastrointestinal bleeding.www.frontiersin.org  October 2010  | Volume 1  |  Article 126  |  5
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(95% CI, 2.39–14.53) compared with individuals using neither ASA 
nor NSAIDs. There was no significant association between oral 
corticosteroid use and the risk of UGIB.
UGIB by the reason for discontinuation, individuals discontinuing 
ASA due to safety concerns had a RR of 2.18 (95% CI, 0.80–5.95) 
compared with current users, while discontinuation for other rea-
sons (primarily non-adherence) was associated with an RR of 0.52 
(95% CI, 0.28–0.99).
Table 4 shows the RR of UGIB associated with various anti-
inflammatory drugs. Compared with non-use, an increased risk 
of UGIB was found in current users of NSAIDs (RR, 2.66; 95% 
CI, 1.66–4.26). The increase in the risk of UGIB was higher in 
those who had been using NSAIDs for less than 31 days (RR, 3.49; 
95% CI, 1.49–8.18) than in those who had been using longer than 
30 days (RR, 2.19; 95% CI, 1.22–3.92) compared with non-users. 
No relationship was found between NSAID dose and the risk of 
UGIB. Concomitant users of ASA and NSAIDs had a RR of 5.90 
Table 1 | The prevalence of demographic and lifestyle characteristics in 
individuals with ugiB and controls with no ugiB, and their association 
with a diagnosis of ugiB, in a cohort of low-dose ASA users.
  Controls   ugiB cases  rr (95% Ci)* 
  N = 2000  N = 169
  n  %  n  % 
Sex
Male  1189  59.5  101 59.8 NA
Female  811  40.6  68 40.2 NA
Age (yeArS)
<65  468  23.4  38 22.5 NA
65–74  670  33.5  58 34.3 NA
≥75  862  43.1  73 43.2 NA
Follow-uP Time (monThS)
0–6  439  21.9  39 23.1 NA
7–12  257  12.8  23 13.6 NA
12–23  428  21.4  35 20.7 NA
24–47  484  24.2  41 24.3 NA
≥48  392  19.6  31 18.3 NA
SmoKing STATuS
Never  878  43.9  59  34.9  1 (–)
Current  276  13.8  28  16.6  1.33 (0.80–2.21)
Former  803  40.2  75  44.4  1.18 (0.81–1.73)
Unknown  43  2.1  7  4.1  2.67 (1.08–6.59)
AlCohol uSe (uniTS/weeK)
0  903  45.1  68  40.2  1 (–)
1–2  262  13.1  26  15.4  1.49 (0.91–2.44)
3–24  599  29.9  46  27 .2  1.11 (0.73–1.70)
≥25  72  3.6  12  7 .1  2.96 (1.43–6.15)
Unknown  164  8.2  17  10.1  1.52 (0.84–2.76)
hoSPiTAlizATionS
None  1616  80.8  112  66.3  1 (–)
1–2  300  15.0  43  25.4  1.88 (1.24–2.86)
≥3  84  4.2  14  8.3  1.56 (0.79–3.05)
hiSTory oF gASTroinTeSTinAl diSeASe
None  1414  70.7  86  50.9  1 (–)
Dyspepsia  450  22.5  49  29.0  1.77 (1.20–2.61)
Peptic ulcer disease  136  6.8  34  20.1  4.59 (2.87–7 .33)
  Uncomplicated  99  5.0  22  13.0  4.18 (2.44–7 .15)
  Complicated  37  1.8  12  7 .1  5.73 (2.73–12.02)
*Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of 
PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, 
NSAIDs and PPIs.
Note: PCP visits, number of referrals and number of hospitalizations were 
collected for the year prior to the index date. A unit per alcohol: 1 unit = 10 ml 
of pure ethanol( 8 g of alcohol). Uncomplicated ulcer diseases: peptic ulcer 
without complication; complicated ulcer diseases: peptic ulcer with bleeding or 
perforation.
ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal anti-in-
flammatory drug; PCP , primary care practitioner; PPI, proton pump inhibitor; PU, 
peptic ulcer; RR, relative risk; UGIB, upper gastrointestinal bleeding.
Figure 5 | Cumulative proportion of patients developing ugiB, stratified 
by age at start date. UGIB, upper gastrointestinal bleeding.
Figure 6 | Cumulative proportion of patients developing ugiB, stratified 
by history of peptic ulcer disease or gastritis/dyspepsia. UGIB, upper 
gastrointestinal bleeding.Frontiers in Pharmacology | Inflammation Pharmacology    October 2010  | Volume 1  |  Article 126  |  6
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discussion
The incidence of UGIB in this cohort of low-dose ASA users was 
1.12 per 1000 person-years. The incidence of UGIB was increased 
more than fivefold in those with a history of peptic ulcer disease, 
confirming the results of other studies that have shown this to be 
the strongest risk factor for UGIB (Hernández-Díaz and García 
Rodríguez, 2006; Lanas et al., 2006).
Current use of 75 mg ASA was associated with a 50% increase 
in RR and use of 150–300 mg ASA with a greater than two-fold 
increase in the risk of UGIB compared with non-use, which is con-
sistent with the results of previous clinical trials and observational 
studies (Weil et al., 1995; Kelly et al., 1996; de Abajo and García 
Rodríguez, 2001; García Rodríguez et al., 2001). Our study also 
shows that discontinuation of low-dose ASA therapy was associated 
with a 30% reduction in the risk of UGIB compared with continua-
tion of therapy, suggesting that the gastric mucosa reverts to its pre-
treatment stage after treatment is withdrawn. When we stratified 
this analysis by the reason for low-dose ASA discontinuation, the 
reduced risk of UGIB was found among those who discontinued 
ASA for reasons unrelated to safety whereas a marked increase in 
the risk of UGIB was found among those who discontinued low-
dose ASA for safety reasons. This strongly suggests a confounding 
by indication (reason for discontinuation) in this latter subgroup 
of discontinuers.
Adding to the literature on the beneficial effects of PPIs in this 
patient group (Lanas et al., 2000, 2006), we also found that con-
comitant PPI use reduces the risk of UGIB in low-dose ASA users 
by almost 50%. The beneficial effect of PPIs was only found if they 
Table 5 presents the RR of UGIB associated with acid-
  suppressing drugs. Current PPI users who initiated this treat-
ment at or before the start date had a significantly reduced risk of 
UGIB compared with non-users (RR, 0.56; 95% CI, 0.33–0.96). 
Current PPI users who initiated this therapy after the start date 
had an increased risk of UGIB, presumably due to confounding 
by indication. The reduced risk of UGIB was found among cur-
rent PPI users who were receiving a medium or high daily dose 
(RR, 0.40; 95% CI, 0.20–0.78), but was not observed among users 
of a low daily dose (RR, 1.00; 95% CI, 0.47–2.12). No significant 
association was found between H2RA use and the risk of UGIB 
(RR, 1.07; 95% CI, 0.47–2.42).
Table 2 | medication use in individuals with ugiB and controls with no 
ugiB, and their association with a diagnosis of ugiB, in a cohort of 
low-dose ASA users.
  Controls  Cases  rr (95% Ci)* 
  N = 2000  N = 169
  n  %  n  % 
low-doSe ASA
Non-use  186  9.3  13  7 .7  1 (–)
Current use (0–30 days)  1570  78.5  136  80.5  1.63 (0.85–3.13)
  75 mg/day  1425  71.2  118  69.8  1.54 (0.80–2.97)
  150–300 mg/day  145  7 .2  18  10.7  2.65 (1.17–5.97)
Past use (31–365 days)  244  12.2  20  11.8  1.31 (0.59–2.88)
CloPidogrel
Non-use  1813  90.6  139  82.2  1 (–)
Current use (0–30 days)  149  7 .4  22  13.0  1.90 (1.12–3.22)
Past use (31–365 days)  38  1.9  8  4.7  2.40 (1.04–5.55)
inTerACTion wiTh CloPidogrel 
Low-dose ASA with  1439  72.0  114  67 .5  1 (–) 
no clopidogrel
Low-dose ASA   103  5.2  14  8.3  1.61 (0.85–3.05) 
plus clopidogrel
wArFArin
Non-use  1907  95.3  161  95.3  1 (–)
Current use (0–30 days)  75  3.8  8  4.7  1.30 (0.57–2.95)
Past use (31–365 days)  18  0.9  0  0.0  –
diPyridAmole
Non-use  1920  96.0  161  95.3  1 (–)
Current use (0–30 days)  65  3.2  8  4.7  1.38 (0.63–3.06)
Past use (31–365 days)  15  0.8  0  0  –
niTrATeS
Non-use  1321  66.1  103  61.0  1 (–)
Current use (0–30 days)  412  20.6  36  21.30  0.93 (0.61–1.42)
Past use (31–365 days)  267  13.3  30  17 .7  1.20 (0.76–1.90)
*Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of 
PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, 
NSAIDs, and PPIs.
Note: Data on PCP visits, number of referrals and number of hospitalizations 
were collected for the year prior to the index date. Data on comorbidity was 
collected for any time before the start date.
ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal 
anti-  inflammatory drug; PCP , primary care practitioner; PPI, proton pump inhibitor; 
PU, peptic ulcer; RR, relative risk; UGIB, upper gastrointestinal bleeding.
Table 3 | The prevalence of low-dose ASA discontinuation in individuals 
with ugiB and controls with no ugiB, and its association with a 
diagnosis of ugiB, in a cohort of low-dose ASA users.
  Controls  ugiB cases  rr (95% Ci)* 
  N = 2000  N = 169
 n  % n % 
low-doSe ASA STATuS
Current users  1494  74.7  131  77 .5  1 (–)
Recent discontinuers  263  13.1  19  11.2  0.71 (0.42–1.20)
Past discontinuers  57  2.9  6  3.6  1.03 (0.40–2.62)
reASon For diSConTinuATion (Among reCenT   diSConTinuerS)
Not safety related†  244  12.2  12  7 .1  0.52 (0.28–0.99)
Safety related  19  0.9  7  4.1  2.18 (0.80–5.95)
*Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of 
PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, 
NSAIDs and PPIs.
†Includes discontinuation due to lack of efficacy, non-adherence or OTC ASA 
use.
Note: The remaining group not included in the table were all individuals who had 
non-use of ASA within the year prior to index date (186 controls and 13 cases) 
Data on PCP visits, number of referrals and number of hospitalizations were 
collected for the year prior to the index date. Data on comorbidity was collected 
for any time before the start date.
ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal anti-in-
flammatory drug; OTC, over-the-counter; PCP , primary care practitioner; PPI, 
proton pump inhibitor; PU, peptic ulcer; RR, incidence rate ratio; UGIB, upper 
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of UGIB compared with non-users, which supports the results of 
other case–control studies (Hallas et al., 2006; Ibáñez et al., 2006). 
The inhibition of platelet aggregation by clopidogrel, in addition 
to causing a vascular homeostatic imbalance, could have a role in 
ulcer healing (Ma et al., 2001; Lanas and Scheiman, 2007), leading 
to a relapse of latent ulcers.
NSAID use was also associated with an increase in the risk of UGIB 
in users of low-dose ASA, but this increase was smaller than that found 
in studies of the general population (Hernández-Díaz and García 
Rodríguez, 2002). This was probably due to our cohort being restricted 
to individuals taking low-dose ASA for secondary prevention of car-
diovascular events. These individuals already have complete inhibition 
of thromboxane-mediated platelet aggregation afforded by aspirin, 
which means that the increase in the risk of UGIB in these individuals 
due to concomitant use of low-dose ASA and NSAIDs is most likely 
a result of directly induced gastrointestinal ulceration.
were initiated at the same time as the low-dose ASA or before the 
first low-dose ASA prescription. Again this suggests a confounding 
by indication for PPI use in those who were not prescribed a PPI 
until sometime after their low-dose ASA prescription. Our data on 
use of H2RAs was limited and we could not assess with precision the 
effect of this drug class. Some studies have shown a protective effect of 
H2RAs on the risk of UGIB among ASA users (Lanas et al., 2007).
We also found that prescribing ASA together with other drugs, 
such as NSAIDs or clopidogrel, confers an increased risk of UGIB. 
Users of clopidogrel had an almost twofold increase in the risk 
Table 4 | Anti-inflammatory drug use in individuals with ugiB and 
controls with no ugiB, and its association with a diagnosis of ugiB, in 
a cohort of low-dose ASA users.
  Controls  ugiB cases  rr (95% Ci)* 
  N = 2000  N = 169
 n  % n % 
nSAids
Non-use  1607  80.3  116  68.6  1 (–)
Current use  156  7 .8  28  16.6  2.66 (1.66–4.26)
  Single NSAID  143  7 .1  24  14.2  2.50 (1.52–4.11)
  Multiple NSAIDs  13  0.7  4  2.4  4.41 (1.33–14.63)
Past use  237  11.8  25  14.8  1.39 (0.86–2.26)
durATion oF nSAid uSe†
≤30 days  33  1.7  8  4.7  3.49 (1.49–8.18)
31–365 days  64  3.2  9  5.3  2.07 (0.97–4.42)
>1 year  46  2.3  7  4.1  2.35 (1.00–5.57)
nSAid doSe†
Low–medium  65  3.2  13  7 .7  3.13 (1.61–6.06)
High  65  3.2  10  5.9  2.10 (1.01–4.34)
Unknown  13  0.6  1  0.6  1.49 (0.19–11.73)
inTerACTion wiTh nSAids
ASA without NSAID  1260  63.0  92  54.4  1 (–)
ASA plus NSAID  133  6.7  26  15.4  2.92 (1.77–4.82)
orAl CorTiCoSTeroidS
Non-use  1891  94.6  159  94.1  1 (–)
Current use (0–30 days)  60  3.0  5  3.0  0.88 (0.33–2.31)
Past use (31–365 days)  49  2.4  5  3.0  0.97 (0.36–2.62)
*Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of 
PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, 
NSAIDs, and PPIs.
†Duration and dose–response was evaluated among current single NSAID 
users. Reference group for duration and dose–response was non-use. Specific 
cut-off values for dose (in mg) were as follows: aceclofenac 200, acemetacin 
120, azapropazone 600, celecoxib 200, diclofenac 100, diflunisal 1500, etodolac 
400, etoricoxib 90, fenbufen 900, fenoprofen 1200, flurbiprofen 150, ibuprofen 
1200, indomethacin 75, ketoprofen 150, ketorolac 30, mefenamic acid 1000, 
meloxicam 7 .5, nabumetone 1000, naproxen 750, piroxicam 10, rofecoxib 25, 
sulindac 200, tenoxicam 10, tiaprofenic 600, and valdecoxib 20. Doses less than 
or equal to the cut-off value were grouped under low–medium doses, and doses 
greater than the cut-off value were grouped under high doses.
Note: Data on PCP visits, number of referrals and number of hospitalizations 
were collected for the year prior to the index date. Data on comorbidity was 
collected for any time before the start date.
ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal 
anti-  inflammatory drug; OTC, over-the-counter; PCP , primary care practitioner; 
PPI, proton pump inhibitor; PU, peptic ulcer; RR, relative risk; UGIB, upper 
gastrointestinal bleeding.
Table 5 | PPi and h2rA use in individuals with ugiB and controls with 
no ugiB, and its association with a diagnosis of ugiB, in a cohort of 
low-dose ASA users.
  Controls   Cases  rr (95% Ci)* 
  N = 2000  N = 169
 n  % n  % 
PPi uSe AT index dATe
Non-use  1490  74.5  107  63.3  1 (–)
Current use (0–30 days)  400  20.0  46  27 .2  0.97 (0.65–1.44)
Past use (31–365 days)  110  5.5  16  9.5  1.30 (0.70–2.41)
PPi uSe AT STArT dATe
Non-use  1490  74.5  107  63.3  1 (–)
Current users initiating PPI   135  6.8  25  14.8  1.88 (1.14–3.13) 
therapy after start date
Current PPI users initiating  265  13.2  21  12.4  0.56 (0.33–0.96) 
PPI at start date
  Low PPI dose†  84  4.2  9  5.3  1.00 (0.47–2.12)
  Medium/high PPI dose†  181  9.0  12  7 .1  0.40 (0.20–0.78)
h2rA AT index dATe
Non-use  1885  94.2  152  89.9  1 (–)
Current use (0–30 days)  84  4.2  12  7 .1  1.08 (0.55–2.11)
Past use (31–365 days)  31  1.6  5  3.0  1.45 (0.51–4.12)
h2rA AT STArT dATe
Non-use  1885  94.2  152  89.9  1 (–)
Current users initiating H2RA  28  1.4  4  2.4  1.09 (0.36–3.31) 
therapy after start date
Current PPI users initiating  56  2.8  8  4.7  1.07 (0.47–2.41) 
H2RA therapy at start date
*Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of 
PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, 
NSAIDs and PPIs.
†Specific cut-off values for daily dose (in mg) were as follows: esomeprazole 10, 
lansoprazole 15, omeprazole 10, rabeprazole 10, pantoprazole 10 mg. Doses less 
than or equal to the cut-off value were grouped under low doses, and doses 
greater than the cut-off value were grouped under medium/high doses.
ASA, acetylsalicylic acid; CI, confidence interval; H2RA, histamine-2 receptor 
antagonist; NSAID, non-steroidal anti-inflammatory drug; PCP , primary care 
practitioner; PPI, proton pump inhibitor; PU, peptic ulcer; RR, relative risk; UGIB, 
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tion of cardiovascular and cerebrovascular events. In addition, 
these data support the finding that combining ASA with NSAIDs 
or clopidogrel increases further the risk of UGIB; while prescrib-
ing a PPI when initiating low-dose ASA therapy reduces the risk 
of UGIB.
Discontinuation of low-dose ASA also reduces the risk of UGIB. 
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discontinue treatment with low-dose ASA are known to be at 
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